Our latest, 'Attribution of NASH as Etiology of Cirrhosis for Clinical Trials Eligibility' in latest issue of @AGA_Gastro - 👏👏👏 congratulations to authors and all working group members!
https://t.co/RBV93oSxtQ
October is Liver Awareness Month. Join us TODAY starting at 3:45 pm ET as FLF joins @MadrigalPharma to ring the @Nasdaq closing bell to increase awareness of the need for more screening & testing to improve diagnosis & staging of #NAFLD#NASH→https://t.co/w9jsxiqsmy #LiverHealth
ELF was just approved as a blood test for fibrosis by @US_FDA and this is an important step in the efforts to develop better tools for diagnosing advanced liver disease and getting away from liver biopsy➡️https://t.co/mtvgF96Em4
#NAFLD#NASH#liverhealth#patientadvocacy#blog
Ani Kardashian on food insecurity & assoc w/all-cause mortality in US adults w/ #NAFLD#ILC2021: food insecurity is ltd or uncertain availability of nutritionally adequate foods or inability to acquire foods in socially acceptable way. 35 million (18 million in USA) experience it
Join us today at #ILC2021 for a live webinar with Prof. Boursier and Prof. Noureddin on #FibroScan-based Scores: Agile 3+, Agile 4, Fast™, to identify early and accurately patients at risk of developing cirrhosis and liver-related complications. https://t.co/qY04Ms79h8
#NAFLD
June 10th is International #NASHDay. Join advocates & partners from across the🌐as we spread awareness about this serious #liverdisease that is on the rise. Together we can make our voices heard! Join the conversation🙌#NASHDay⮕https://t.co/yxJboTAUGK #NAFLD#NASH@GlobalLiver
I don't know that this is news really but I was one of the patient advocates interviewed for an extensive article in @PharmaVOICE about the need for industry to include patients in the process of drug development⮕https://t.co/AnS6azw3Rd
#NASH#NAFLD#PatientAdvocacy
Nonalcoholic fatty liver disease (#NAFLD) is the most common #ChronicLiverDisease (#CLD) in children worldwide.
Our very own Dr. Veronica Miller & the @LiverForum Pediatric Working Group explore research for a “silver bullet” treatment.
https://t.co/WQNSvr6C9Q
A new paper from BPH's Dr. Veronica Miller & the @LiverForum Pediatric Working Group combs through the research for a “silver bullet” treatment for nonalcoholic fatty liver disease (#NAFLD), the most common #ChronicLiverDisease in children worldwide. https://t.co/e5G8AovHyy
Today is #WorldCancerDay, 4 Feb.
Did you know? #Livercancer is the 3rd-leading cause of cancer-related deaths🌐worldwide. What are the main causes of liver cancer?
➡️https://t.co/KBbGVsBFGo
To find out more, consult our new infographic, Liver Cancer Explained.
@EASLedu
INDUSTRY STAKEHOLDERS: Get email updates from the CDER Small Business and Industry Assistance (SBIA) program to learn about:
🟠 Industry news
🟠 New guidances
🟠 Meetings & conferences
🟠 Educational tutorials
🟠 Webinars
🟠 And more!
Sign up here: https://t.co/0p0VED2pMw
The Translational Science Interagency Fellowship sponsored by FDA & @ncats_nih_gov is looking for individuals interested in bringing safe & effective drugs, regimens, and devices from the bench to the bedside as quickly as possible.
Apply now: https://t.co/vgfx9ivOSp
Don't miss this #webcast on January 29th as the @US_FDA will provide a summary of the agency's current thinking on the published draft guidance📄 & regulatory pathways for development of drugs for treatment of #NASH👉https://t.co/tJqrCtrUJF
Learn about FDA’s table of surrogate endpoints that provides transparency, coherency, and consistency for stakeholders seeking to design effective drug development programs in the latest #CDERImpactStory: https://t.co/mStup6052u
Today we’re launching the International Liver Congress™ 2021 https://t.co/x7uFDwD2MJ Clear your agendas for Wed to Sat, 23–26 June. Prepare to send in your abstracts & register for #EASL’s flagship #ILC2021 on beating liver disease together. Share this with your peers! @EASLedu